The DOI matches its Crossref record, with a small difference in title or year; 6 of the 6 references it cites were found in a registry or an index.
RETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most in vivo mouse studies of retromer in AD have been performed in transgenic mice overexpressing human mutations in APP and PSEN1/2 or FTD-associated mutations in the tau gene MAPT.
“most in vivo mouse studies have been performed in transgenic mice engineered to overexpress human mutations in APP and PSEN1/2 (Wen et al., 2011; Li et al., 2019a) or FTD-associated mutations in the tau gene MAPT (Vagnozzi et al., 2019; Carosi et al., 2020).”
From The neuronal retromer can regulate both neuronal and microglial phenotypes of Alzheimer's disease (2022) · cites this paper as Vagnozzi et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734
Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.378 · Cited by 526
Retromer: A Master Conductor of Endosome Sorting
Burd, C., & Cullen, P. J. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016774 · Cited by 435
VPS35 haploinsufficiency increases Alzheimer’s disease neuropathology
Wen, L., Tang, F.-L., Hong, Y., Luo, S.-W., Wang, C.-L., He, W., Shen, C., Jung, J.-U., Xiong, F., Lee, D.-H., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201105109 · Cited by 270
Muhammad, A., Flores, I., Zhang, H., Yu, R., Staniszewski, A., Planel, E., Herman, M., Ho, L., Kreber, R., Honig, L. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802545105 · Cited by 248
Flagged first, then by citations
Research works printed but not linked: 35
- O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 2011;34:185–204. · DOI · Paper page
- Choy RW-Y, Chen Z, Schekman R. Amyloid precursor protein traffics from the cell surface via endosomes for amyloid beta production in the trans-Golgi network. Proc Natl Acad Sci USA. 2012;109:E2077–E2088. · DOI
- Trousdale C, Kim K. Retromer: structure, function, and roles in mammalian disease. Eur J Cell Biol 2015;94:513–21. · DOI
- Wang S, Bellen HJ. The retromer complex in development and disease. Development. 2015;142:2392–6. · DOI
- Temkin P, Lauffer B, Jager S, Cimermancic P, Krogan NJ, von Zastrow M. SNX27-mediates retromer tubule entry and endosome-to-plasma membrane trafficking of signaling receptors. Nat Cell Biol 2011;13:715–21. · DOI · Paper page
- Nielsen MS, Gustafsen C, Madsen P, Nyengaard JR, Hermey G, et al. Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA. Mol Cell Biol 2007;27:6842–51. · DOI · Paper page
- Fjorback AW, Seaman M, Gustafsen C, Mehmedbasic A, Gokool S, et al. Retromer binds the FANSHY soring motif in SorLA to regulate amyloid precursor protein sorting and processing. J Neurosci 2012;32:1467–80. · DOI · Paper page
- Small SA, Kent K, Pierce A, Leung C, Kang MS, et al. Model-guided microarray implicates the retromer complex in Alzheimer’s disease. Ann Neurol 2005;58:909–19. · DOI · Paper page
- Vardarajan BN, Bruesegem SY, Harbour ME, Inzelberg R, Friedland R, et al. Identification of Alzheimer’s disease-associated variants in genes that regulate retromer function. Neurobiol Aging. 2012;33:2231.e15–2231.e30. · DOI · Paper page
- Chu J, Praticò D. The retromer complex system in a transgenic mouse model of AD: influence of age. Neurobiol Aging 2017;52:32–38. · DOI
- Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Pratico D. Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Mol Neurodegener 2012;7:1. · DOI
- Vagnozzi AN, Giannopoulos PF, Praticò D. Brain 5-lipoxygenase overexpression worsens memory, synaptic integrity, and tau pathology in the P301S mice. Aging Cell 2018;17:e12695. · DOI
- Di Meco A, Lauretti E, Vagnozzi AN, Praticò D. Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer’s disease mice. Neurobiol Aging. 2014;35:2458–64. · DOI
- Li JG, Chu J, Barrero C, Merali S, Praticò D. Homocysteine exacerbates β‐amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol 2014;75:851–63. · DOI
- Vagnozzi AN, Giannopoulos PF, Praticò D. The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy. Transl Psychiatry 2017;18:1288. · DOI
- Lauretti E, Li JG, Di Meco A, Praticò D. Glucose deficit triggers tau pathology and synaptic dysfunction in a tauopathy mouse model. Transl Psychiatry 2017;7:e1020. · DOI
- Li, JG, Chu, J, Praticò, D. Downregulation of autophagy by 12/15Lipoxygenase worsens the phenotype of an Alzheimer’s disease mouse model with plaques, tangles, and memory impairments. Mol Psychiatry. 2018. https://doi.org/10.1038/s41380-018-0268-1. · DOI
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402–8. · DOI · Paper page
- Giannopoulos, PF, Chu, J, Praticò, D. Learning impairments, memory deficits, and neuropathology in aged tau transgenic mice are dependent on leukotrienes biosynthesis: role of the cdk5 kinase pathway. Mol Neurobiol. 2018. https://doi.org/10.1007/s12035-018-1124-7. · DOI
- Miura E, Hasegawa T, Konno M, Suzuki M, Sugeno N, et al. VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson’s disease. Neurobiol Dis 2014;71:1–13. · DOI
- Chu J, Li JG, Hoffman NE, Stough AM, Madesh M, Praticò D. Regulation of gamma-secretase activating protein by the 5Lipoxygenase: in vitro and in vivo evidence. Sci Rep 2015;5:11086. · DOI
- Lauretti E, Praticò D. Glucose deprivation increases tau phosphorylation via P38 mitogen-activated protein kinase. Aging Cell. 2015;14:1067–74. · DOI
- Mecozzi VJ, Berman DE, Simoes S, Vetanovetz C, Awal MR, et al. Pharmacological chaperones stabilize retromer to limit APP processing. Nat Chem Biol 2014;10:443–9. · DOI · Paper page
- Kim E, Lee Y, Lee HJ, Kim JS, Song BS, et al. Implication of mouse VPS26b-VPS29-VPS35 retromer complex in sortilin trafficking. Biochem Biophys Res Commun 2010;403:167–71. · DOI
- Lee MJ, Lee JH, Rubinsztein DC. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Progr Neurobiol 2013;105:49–59. · DOI · Paper page
- Zhang Y, Chen X, Zhao Y, Ponnusamy M, Liu Y. The role of ubiquitin proteasomal system and autophagy-lysosomal pathway in Alzheimer’s disease. Rev Neurosci 2017;28:861–8. · DOI
- Zang JY, Liu SJ, Li HL, Wang JZ. Microtubule-associated protein tau is a substrate of ATP/Mg (2+)-dependent proteasome protease system. J Neural Transm 2005;112:547–55. · DOI
- Hamano T, Gendron TF, Causevic E, Yen SH, Lin WL, et al. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci. 2018;27:119–1130.
- Schuur M, Ikram MA, van Swieten JC, Isaacs A, Vergeer-Drop JM, et al. Cathepsin D gene and the risk of Alzheimer’s disease: a population-based study and meta-analysis. Neurobiol Aging. 2011;32:1607–1614. · DOI
- Chai, YL, Chong, JR, Weng, J, Howlett, D, Halsey, A, et al. Lysosomal cathepsin D is upregulated in Alzheimer’s disease neocortex and may be a marker for neurofibrillary degeneration. Brain Pathol. 2018. https://doi.org/10.1111/bpa.12631. · DOI · Paper page
- Follett J, Norwood SJ, Hamilton NA, Mohan M, Kovtun O. The VPS35 D620N mutation linked to Parkinson’s disease disrupts the cargo sorting function of retromer. Traffic. 2014;15:230–44. · DOI
- Seaman MNJ. Cargo‐selective endosomal sorting for retrieval to the Golgi requires retromer. J Cell Biol. 2004;165:111–22. · DOI · Paper page
- Kenessey A, Nacharaju P, Ko L, Yen S. Degradation of Tau by lysosomal enzyme cathepsin D: implication for alzheimer neurofibrillary degeneration. J Neurochem 1997;69:2026–38. · DOI
- Williams ET, Chen X, Moore DJ. VPS35, the retromer complex, and Parkinson’s disease. J Parkinsons Dis. 2017;7:219–33. · DOI
- Li JG, Chiu J, Praticò D. Full recovery of the Alzheimer’s disease phenotype by gain of function of Vacuolar Protein Sorting 35. Mol. Psychiatry. 2019. https://doi.org/10.1038/s41380-019-0364-x. (Epub ahead of print) · DOI
Cited by
Sorted by citations
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Receptor Recycling by Retromer
Carosi, J. M., Denton, D., Kumar, S., & Sargeant, T. J. (2023) · Molecular and Cellular Biology · doi:10.1080/10985549.2023.2222053 · Cited by 36
The neuronal retromer can regulate both neuronal and microglial phenotypes of Alzheimer's disease
Qureshi, Y. H., Berman, D. E., Marsh, S. E., Klein, R. L., Patel, V. M., Simoes, S., Kannan, S., Petsko, G. A., Stevens, B., & Small, S. A. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110262 · Cited by 31
Retromer dysfunction at the nexus of tauopathies
Carosi, J. M., Denton, D., Kumar, S., & Sargeant, T. J. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00727-2 · Cited by 16
Ramonet, D., Daerr, A., & Hallbeck, M. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02096-8 · Cited by 7
Metadata
- Authors
- Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D.
- Venue
- Molecular Psychiatry
- Published
- 2019-07-09
- Volume
- 26
- Issue
- 11
- Pages
- 6992-7005
- ISSN
- 1359-4184
- 1476-5578
- PMC
- PMC6949432
- Cited by
- 36
- References
- 6
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2023-01-25)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review